Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision Biosciences Inc (NQ: DTIL )

8.940 -0.020 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,871
Open 8.900
Bid (Size) 8.750 (4)
Ask (Size) 9.570 (1)
Prev. Close 8.960
Today's Range 8.810 - 9.090
52wk Range 8.250 - 19.43
Shares Outstanding 113,793,338
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire

Performance

YTD
-19.46%
-19.46%
1 Month
-5.60%
-5.60%
3 Month
-10.24%
-10.24%
6 Month
-7.64%
-7.64%
1 Year
+0.37%
+0.37%

More News

Read More
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming August Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Second Quarter Results on August 1, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces its Addition to the Russell Microcap® Index
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report First Quarter Results on May 13, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.